Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD
- Conditions
- Exudative Macular DegenerationRetinal Hemorrhage
- Interventions
- Registration Number
- NCT01835067
- Lead Sponsor
- King's College Hospital NHS Trust
- Brief Summary
This study will recruit patients who have recently had a submacular haemorrhage (bleed under the part of the retina responsible for detailed vision), as a complication of wet age-related macular degeneration (wet AMD). Wet AMD is a very common disease where abnormal blood vessels form under the retina and leak, causing a significant reduction in vision.
The study will investigate treatment of the bleed with various combinations of the two drugs: tissue plasminogen activator (tPA) - designed to dissolve the blood clot; and perfluoropropane (C3F8) - designed to shift the blood clot away from the central part of the retina (the macula). tPA is a commonly used 'clot-buster' drug for the treatment of stroke. C3F8 is a gas commonly used in eye surgery. Patients recruited will be divided into four groups: control group that receive none of the above drugs; one group that receives only tPA; one group that receives only C3F8; and one group that receives both.
All patients will receive the current gold standard treatment for wet AMD, ranibizumab (Lucentis®).
The aim of the study is to improve vision in a condition, which left untreated, would cause severe visual loss.
- Detailed Description
Age-related macular degeneration (AMD) is the commonest cause of blindness worldwide. Its prevalence increases with age, being relatively rare under 60 years and reaching its peak incidence in those older than 80 years. AMD principally affects central vision, which is responsible for the ability to see fine detail and the disease rapidly destroys the ability to read normal print, recognise faces, drive, and watch television. It can therefore have a profound effect on quality of life.
There are two main forms of AMD; the dry form, in which there is slow degeneration of the cells responsible for sight, resulting in gradual visual loss; and the wet form (neovascular), which occurs when abnormal blood vessels (choroidal neovascularisation) grow under the retina, the part of the eye which is responsible for sensing light, like the film of a camera. These new blood vessels have weak walls leading to leakage of fluid (oedema), and sometimes significant amounts of bleeding (submacular haemorrhage - SMH). These rapidly lead to central visual distortion and blurring. Although the dry form is commoner, the wet form more commonly results in profound central visual loss and is responsible for the majority of cases that ultimately require blind registration.
The current best treatment ('gold-standard') for wet AMD is the drug ranibizumab (Lucentis®), which aims to shrink and destroy the abnormal blood vessels responsible for the visual symptoms. In several trials ranibizumab has been shown to improve vision in patients with wet AMD.
It is not uncommon for patients with wet AMD to develop SMH, which when it occurs, significantly reduces the patient's visual prognosis. SMH is thought to have a number of toxic consequences on the retinal function.
This study investigates the use of two drugs: tissue plasminogen activator (tPA), a 'clot-buster' drug used to treat stroke, which is designed to dissolve the clot over the central retina (macula); and perfluoropropane (C3F8), a gas commonly used in retinal surgery, which is designed to displace the clot away from the macula.
This study is a randomized, double-masked, clinical trial with a recruitment target of 55 people with SMH and wet AMD. Participants will be allocated to one of four groups; a control group receiving none of the above drugs; one group receiving only tPA; one group receiving only C3F8; and one group receiving both. All patients will receive the 'gold-standard' treatment of ranibizumab for their underlying wet AMD. We aim to determine if tPA and/or C3F8 produce a visual outcome that is superior to standard care, with a favourable safety profile. We will also measure the size of the blood clot and scarring using computer analysis of macula photographs.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 55
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description C3F8 Only Group (B) C3F8 Gas C3F8 given. Ranibizumab given as standard. tPA and C3F8 Group (C) Ranibizumab Both C3F8 gas and tPA given. Ranibizumab given as standard. tPA Only Group (D) tPA tPA given. Ranibizumab given as standard. tPA and C3F8 Group (C) C3F8 Gas Both C3F8 gas and tPA given. Ranibizumab given as standard. tPA and C3F8 Group (C) tPA Both C3F8 gas and tPA given. Ranibizumab given as standard. C3F8 Only Group (B) Ranibizumab C3F8 given. Ranibizumab given as standard. Control Group (A) Ranibizumab Ranibizumab only (active control). Participants will receive a 'sham injection' to simulate C3F8 and/or tPA administration. tPA Only Group (D) Ranibizumab tPA given. Ranibizumab given as standard.
- Primary Outcome Measures
Name Time Method Mean ETDRS visual acuity 3 months
- Secondary Outcome Measures
Name Time Method Mean ETDRS visual acuity 1 and 12 months Percentage patients 15 letters or greater improvement in ETDRS visual acuity 12 months Percentage patients 0 letters or greater improvement in ETDRS visual acuity 12 months Percentage patients 15 letters or greater loss in ETDRS visual acuity 12 months Mean total area of macular haemorrhage on colour fundus photography 1, 3 and 6 months Greatest linear dimension of macular haemorrhage on colour fundus photography 1, 3 and 6 months Presence of subfoveal blood on colour fundus photography 1 month
Trial Locations
- Locations (5)
Maidstone Hospital
🇬🇧Maidstone, Kent, United Kingdom
Sunderland Eye Infimary
🇬🇧Sunderland, Tyne And Wear, United Kingdom
Hull & East Yorkshire Hospital NHS Trust
🇬🇧Hull, United Kingdom
King's College Hospital NHS Foundation Trust
🇬🇧London, United Kingdom
Southend University Hospital NHS Foundation Trust
🇬🇧Southend, United Kingdom
Maidstone Hospital🇬🇧Maidstone, Kent, United Kingdom